The company's financial foundation is rapidly eroding, with total assets declining to $93.5 million in 2026Q1 while the accumulated deficit has ballooned to $320.1 million.
| Total Current Assets | 49.73M | 40.77M | 47.6M | 61.34M | 90.13M | 110.25M | 13.73M | 21.55M |
| Cash & Short-Term Investments | 47.4M | 39.2M | 46.24M | 49.08M | 82.7M | 105.11M | 13.53M | 21.39M |
| Cash Only | 4.17M | 3.94M | 4.04M | 3.88M | 29.88M | 58.93M | 13.53M | 21.39M |
| Short-Term Investments | 43.23M | 35.26M | 42.19M | 45.2M | 52.83M | 46.18M | 0 | 0 |
| Accounts Receivable | 11K | 12K | 34K | 11.47M | 6.11M | 3.14M | 2K | 1K |
| Days Sales Outstanding | 86.45 | 54.07 | 161.17 | 13.68K | 8.33K | 13.99K | 29.2 | 10.14 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.31M | 1.56M | 19K | 795K | 1.31M | 0 | 0 | 0 |
| Total Non-Current Assets | 43.82M | 61.16M | 24.98M | 34.1M | 26.2M | 36.78M | 1.06M | 1.71M |
| Property, Plant & Equipment | 1.1M | 1.15M | 1.85M | 3.18M | 3.06M | 1.77M | 965K | 1.64M |
| Fixed Asset Turnover | 0.05x | 0.07x | 0.04x | 0.10x | 0.09x | 0.05x | 0.03x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 881K | 910K | 1.03M | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 184.01M | 0 | 21.97M | 30.84M | 21.33M | 34.85M | 0 | 0 |
| Other Non-Current Assets | 41.84M | 59.1M | 124K | 77K | 1.82M | 157K | 98K | 72K |
| Total Assets | 93.54M | 101.93M | 72.58M | 95.44M | 116.33M | 147.03M | 14.8M | 23.26M |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | 88.25% | 40.45% | -23.96% | -17.96% | -20.88% | 893.71% | -36.39% | - |
| Total Current Liabilities | 23.42M | 24.19M | 24.77M | 24.44M | 15.54M | 8.41M | 11.24M | 5.9M |
| Accounts Payable | 767K | 862K | 1.97M | 1.05M | 1.55M | 1.2M | 441K | 748K |
| Days Payables Outstanding | 2.05K | 1.92K | 8.76K | 1.82K | 2.93K | 11.81K | 14.63K | 15.17K |
| Short-Term Debt | 0 | 2K | 0 | 0 | 0 | 0 | 8.03M | 3.67M |
| Deferred Revenue (Current) | 60.94M | 20.32M | 0 | 20.23M | 9.08M | 3.12M | 0 | 0 |
| Other Current Liabilities | 2.34M | 3.01M | 20.52M | 926K | 1.07M | 3.56M | 321K | 294K |
| Current Ratio | 2.12x | 1.69x | 1.92x | 2.51x | 5.80x | 13.11x | 1.22x | 3.65x |
| Quick Ratio | 2.12x | 1.69x | 1.92x | 2.51x | 5.80x | 13.11x | 1.22x | 3.65x |
| Cash Conversion Cycle | -1.96K | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.5M | 2.34M | 2K | 840K | 1.85M | 54K | 614K | 6.4M |
| Long-Term Debt | 2.5M | 0 | 0 | 0 | 0 | 0 | 348K | 5.44M |
| Capital Lease Obligations | 2.44M | 2.34M | 2K | 840K | 1.85M | 54K | 127K | 134K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 139K | 823K |
| Total Liabilities | 25.92M | 26.52M | 24.77M | 25.28M | 17.39M | 8.46M | 11.86M | 12.3M |
| Total Debt | 2.5M | 2.34M | 840K | 1.86M | 2.83M | 128K | 8.57M | 9.31M |
| Net Debt | -1.67M | -1.6M | -3.2M | -2.02M | -27.05M | -58.8M | -4.96M | -12.07M |
| Debt / Equity | 0.04x | 0.03x | 0.02x | 0.03x | 0.03x | 0.00x | 2.92x | 0.85x |
| Debt / EBITDA | -0.07x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.05x | - | - | - | - | - | - | - |
| Interest Coverage | -11032.00x | -4056.00x | -1173.93x | -657.95x | -723.36x | -45.93x | -9.79x | -7.38x |
| Total Equity | 67.62M | 75.41M | 47.8M | 70.16M | 98.94M | 138.56M | 2.94M | 10.96M |
| Equity Growth % | 127.12% | 57.75% | -31.86% | -29.09% | -28.59% | 4613.06% | -73.17% | - |
| Book Value per Share | 1.35 | 1.58 | 1.44 | 2.25 | 3.20 | 4.50 | 0.16 | 0.61 |
| Total Shareholders' Equity | 67.62M | 75.41M | 47.8M | 70.16M | 98.94M | 138.56M | 2.94M | 10.96M |
| Common Stock | 4K | 4K | 3K | 3K | 3K | 3K | 0 | 0 |
| Retained Earnings | -320.12M | -311.72M | -279.79M | -246.9M | -210.65M | -166.47M | -131.46M | -111.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 16K | 262K | 60K | -15K | -981K | -183K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and solvency
As reported in recent SEC filings, total assets have declined from $118.2 million in 2025Q1 to $93.5 million in 2026Q1, signaling a persistent contraction in the company's resource base as it fails to achieve commercial scale for its diagnostic offerings.
The consistent decline in total assets alongside a widening accumulated deficit suggests that the company is consuming its capital base to fund ongoing operating losses. This trajectory indicates that the business model has yet to reach a self-sustaining inflection point, leaving the balance sheet increasingly fragile.
Based on the most recent quarterly data, the company's cash position has dwindled to $4.2 million, which, when viewed against historical quarterly burn rates, suggests an extremely limited runway that warrants immediate investor concern regarding the firm's ability to continue as a going concern.
While the current ratio of 2.12 appears superficially healthy, it is heavily influenced by deferred revenue and other non-cash current liabilities rather than liquid assets. The rapid depletion of cash reserves implies that the company may be forced to seek dilutive financing or pursue strategic alternatives in the near term.
According to financial statements, the company's retained earnings have plummeted to a deficit of $320.1 million as of 2026Q1, reflecting years of significant capital consumption without a corresponding build-up in commercial value or sustainable revenue generation.
The erosion of equity highlights the high cost of clinical validation and market development that has not yet translated into shareholder value. Investors should monitor whether future equity raises will be required to offset this persistent deficit, which would further dilute existing ownership stakes.
As disclosed in the balance sheet, the presence of $20.3 million in deferred revenue creates a potential distortion in liquidity metrics, as this liability represents future performance obligations rather than cash available for immediate operational needs.
The reliance on deferred revenue as a significant component of the liability structure suggests that the company has received upfront payments for services not yet fully rendered or recognized. This accounting treatment may mask the true severity of the cash-burning nature of the business by inflating current liabilities without providing a corresponding cash buffer.
Quick answers to the most common questions about buying SERA stock.
As of 2025, Sera Prognostics, Inc. (SERA) had total assets of $101.9M including $40.8M in current assets.
Sera Prognostics, Inc. (SERA) carries total debt of $2.3M, offset by $39.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Sera Prognostics, Inc. (SERA) has total shareholders' equity (book value) of $75.4M ($1.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Sera Prognostics, Inc. (SERA) reported a current ratio of 1.69x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.